日本无限资源_福禄影院午夜伦_美国av毛片_亚洲自拍在线观看_激情亚洲一区国产精品_999久久久久

 
Novel HIV vaccine candidate induces immune responses in humans, monkeys: study
                 Source: Xinhua | 2018-07-08 03:50:28 | Editor: huaxia

The file photo shows that a nurse tests a blood sample during a free HIV test at a blood tests party, part of a campaign to prevent HIV infection among male same-sex couples, in Bangkok, Thailand, Sept. 20, 2014. (REUTERS Photo)

WASHINGTON, July 7 (Xinhua) -- A new study published on Friday in the Lancet showed that an experimental, preventive HIV-1 vaccine regimen was well-tolerated and generated comparable and robust immune responses against HIV in healthy adults and rhesus monkeys.

Also, the vaccine candidate provided 67 percent protection against infection with an HIV-like virus in monkeys, according to the study.

Based on the results from phase 1 and phase 2a clinical trials that involved nearly 400 healthy adults in Rwanda, South Africa, Thailand, Uganda and the United States, a phase 2b trial has been initiated in southern Africa to determine the safety and efficacy of the HIV-1 vaccine candidate in 2,600 women at risk for acquiring HIV.

This is one of only five experimental HIV-1 vaccine concepts that have progressed to efficacy trials in humans in the 35 years of the global HIV/AIDS epidemic.

Previous HIV-1 vaccine candidates have typically been limited to specific regions of the world. The experimental regimens tested in this study are based on 'mosaic' vaccines that take pieces of different HIV viruses and combine them to elicit immune responses against a wide variety of HIV strains.

"This study demonstrates that the mosaic Ad26 prime, Ad26 plus gp140 boost HIV vaccine candidate induced robust immune responses in humans and monkeys with comparable magnitude, kinetics, phenotype, and durability," said Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, who led the study.

Almost 37 million people worldwide are living with HIV/AIDS, with an estimated 1.8 million new cases every year. A safe and effective preventative vaccine is urgently needed to curb the HIV pandemic.

In the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans, and only one has provided evidence of protection in an efficacy trial in Thailand, which lowered the rate of human infection by 31 percent but the effect was considered too low to advance the vaccine to common use.

The Ad26/Ad26 plus gp140 vaccine candidate induced the greatest immune responses in humans and also provided the best protection in monkeys, resulting in complete protection against infection of SHIV, a virus similar to HIV that infects monkeys, in two-thirds of the vaccinated animals.

However, researchers said these results should be interpreted cautiously.

"The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection," said Barouch.

The authors also noted the relevance of vaccine protection in rhesus monkeys to clinical efficacy in humans remains unclear, and there was no definitive immunological measurement that was known to predict protection against HIV-1 in humans.

Back to Top Close
Xinhuanet

Novel HIV vaccine candidate induces immune responses in humans, monkeys: study

Source: Xinhua 2018-07-08 03:50:28

The file photo shows that a nurse tests a blood sample during a free HIV test at a blood tests party, part of a campaign to prevent HIV infection among male same-sex couples, in Bangkok, Thailand, Sept. 20, 2014. (REUTERS Photo)

WASHINGTON, July 7 (Xinhua) -- A new study published on Friday in the Lancet showed that an experimental, preventive HIV-1 vaccine regimen was well-tolerated and generated comparable and robust immune responses against HIV in healthy adults and rhesus monkeys.

Also, the vaccine candidate provided 67 percent protection against infection with an HIV-like virus in monkeys, according to the study.

Based on the results from phase 1 and phase 2a clinical trials that involved nearly 400 healthy adults in Rwanda, South Africa, Thailand, Uganda and the United States, a phase 2b trial has been initiated in southern Africa to determine the safety and efficacy of the HIV-1 vaccine candidate in 2,600 women at risk for acquiring HIV.

This is one of only five experimental HIV-1 vaccine concepts that have progressed to efficacy trials in humans in the 35 years of the global HIV/AIDS epidemic.

Previous HIV-1 vaccine candidates have typically been limited to specific regions of the world. The experimental regimens tested in this study are based on 'mosaic' vaccines that take pieces of different HIV viruses and combine them to elicit immune responses against a wide variety of HIV strains.

"This study demonstrates that the mosaic Ad26 prime, Ad26 plus gp140 boost HIV vaccine candidate induced robust immune responses in humans and monkeys with comparable magnitude, kinetics, phenotype, and durability," said Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, who led the study.

Almost 37 million people worldwide are living with HIV/AIDS, with an estimated 1.8 million new cases every year. A safe and effective preventative vaccine is urgently needed to curb the HIV pandemic.

In the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans, and only one has provided evidence of protection in an efficacy trial in Thailand, which lowered the rate of human infection by 31 percent but the effect was considered too low to advance the vaccine to common use.

The Ad26/Ad26 plus gp140 vaccine candidate induced the greatest immune responses in humans and also provided the best protection in monkeys, resulting in complete protection against infection of SHIV, a virus similar to HIV that infects monkeys, in two-thirds of the vaccinated animals.

However, researchers said these results should be interpreted cautiously.

"The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection," said Barouch.

The authors also noted the relevance of vaccine protection in rhesus monkeys to clinical efficacy in humans remains unclear, and there was no definitive immunological measurement that was known to predict protection against HIV-1 in humans.

010020070750000000000000011100001373090261
主站蜘蛛池模板: 一区日韩在线 | 国产第一区| 国产大学生一级毛片绿象 | 久久国产视频精品 | 亚洲国产婷婷影院 | 一级免费特黄视频 | 第一次爱的人免费看电视 | 狠狠插网站 | 国产伦精品久久久一区二区三区 | 久久精品国产91精品亚洲高清 | 已婚丰满少妇21P | 在线观看成人网 | 国产bdsm | haodiaocao的视频这里看 | 国产超碰人人模人人爽人人添 | 5252aⅴ爱我愿haose016色 | 国产黄色网址大全 | 国产欧美综合在线观看第十页 | 噜噜色噜噜| 国产精品美女久久久av超清 | 精品久久久久久久久久国产潘金莲 | 国产丰满乱子伦无码一区二区 | 亚洲综合久久av一区二区三区 | 欧美日韩中字 | 无码专区国产精品视频 | 奇米影视777me| 日本黄色一级片视频 | 亚洲激情成人网 | 国产三级国产精品 | 黑人玩弄人妻中文在线 | 亚洲国产精品日本无码网站 | 国产亚洲日韩在线三区 | 特级毛片片A片AAAAAA | 欧美国产精品天堂 | 宅男噜噜噜66国产精品86 | 亚洲AV无码乱码在线观看看 | 亚洲区小说区激情区图片区 | 蜜桃无码AV一区二区 | 日本熟妇牲交视频 | 日韩在线观看中文 | 99插插 |